Help

BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

International

Johnson & Johnson fined nearly $30 million for impeding generic drugs to market

December 21, 2017 Reprints

France's competition regulator has fined U.S. healthcare firm Johnson & Johnson Inc. $29.6 million after it found that the company had deliberately slowed market access to generic copies of its painkiller Durogesic, CNBC reported citing Reuters. The regulator said that Johnson & Johnson's unit Janssen-Cilag S.A.S. had "repeatedly intervened" to block the approval processes of Durogesic's generic copies and disparaged them when in contact with healthcare professionals. The case was filed by German pharmaceutical firm Ratiopharm GmbH.

Help

Johnson & Johnson fined nearly $30 million for impeding generic drugs to market

Readers Poll

Most Read in International

Sign up now for free access to this article and much more.

If you are already registered with Business Insurance, click here to Login

Please tell us a bit more about yourself in order to continue

About

Advertise

Reprints and Licensing

Resources